Definium Therapeutics, a clinical-stage biopharmaceutical focused on pharmaceutically optimized psychedelic treatments for brain disorders such as generalized anxiety disorder (GAD) and major depressive disorder (MDD), is advancing Phase 3 trials of its lead candidate DT120 ODT following FDA breakthrough designation and favorable Phase 2b data. Despite scientific progress, the company continues to operate at substantial net losses, reaching approximately $184 million in 2025. Liquidity remains strong with cash reserves supporting ongoing development, though reliance on third-party manufacturing and regulatory uncertainties present ongoing risks.